J. Gu

发表

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

R. Sarangapani, Jessie Gu, A. Noè, 2010, Journal of clinical pharmacology.

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

I. Ostrovnaya, N. Cheung, Jessie W Gu, 2016, Pediatric blood & cancer.

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A. Zelenetz, I. Flinn, T. Kipps, 2013 .

Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism

R. Woessner, M. Kagan, M. Walles, 2021, Drug Metabolism and Disposition.

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021 .

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

A. Tolcher, E. Felip, L. Paz-Ares, 2023, Journal of Clinical Oncology.

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).

J. Byrd, J. Leonard, I. Flinn, 2013 .

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

A Study to Evaluate Relative Bioavailability, Food Effect, and Pharmacodynamics of Tropifexor, a Farnesoid X Receptor Agonist, in Healthy Participants

R. Woessner, L. Klickstein, W. Prince, 2022, Clinical pharmacology in drug development.

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

R. Heist, F. Meric-Bernstam, K. Yoh, 2021 .

Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment

R. Woessner, W. Prince, R. Stringer, 2021, Journal of clinical pharmacology.